We are looking forward to meeting pharmaceutical and biotech companies, investors and potential partners to discuss Lys Therapeutics and the development of #LYS241, our first-in-class monoclonal antibody targeting the pathological tPA–NMDAr interaction.

𝗟𝗬𝗦𝟮𝟰𝟭 is being developed as a pipeline-in-a-product opportunity across several neurological indications, with our current priorities including 𝗠𝘂𝗹𝘁𝗶𝗽𝗹𝗲 𝗦𝘆𝘀𝘁𝗲𝗺 𝗔𝘁𝗿𝗼𝗽𝗵𝘆, 𝗣𝗮𝗿𝗸𝗶𝗻𝘀𝗼𝗻’𝘀 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗮𝗻𝗱 𝗮𝗰𝘂𝘁𝗲 𝗶𝘀𝗰𝗵𝗲𝗺𝗶𝗰 𝘀𝘁𝗿𝗼𝗸𝗲.

With our 𝗜𝗡𝗗-𝗲𝗻𝗮𝗯𝗹𝗶𝗻𝗴 𝗽𝗿𝗼𝗴𝗿𝗮𝗺 𝗻𝗲𝗮𝗿𝗶𝗻𝗴 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗼𝘂𝗿 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗽𝗿𝗼𝗴𝗿𝗮𝗺 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗶𝗻𝗴, this is an important time for Lys Therapeutics.

We will be in Yokohama from October 7 to October 9, to connect with companies interested in neuroscience, neurodegeneration, neurovascular biology and first-in-class therapeutic innovation.

📍 PACIFICO Yokohama
📅 October 7–9, 2026

Looking forward to three intense days of meetings and discussions in Japan.

#BioJapan #LysTherapeutics #LYS241 #Neuroscience #Neurodegeneration #MSA #ParkinsonsDisease #Stroke #Biotech #BusinessDevelopment #Partnering